Pii
Hunt Valley, Maryland, United States
Program data pending ClinicalTrials.gov matching
Profiled
Not yet scored
✓ FDA Inspections (4)
○ Clinical Trials
○ SEC Filings
✓ Press (10)
○ EMA GMP
✓ MHRA GMP (2)
Quick Facts: Pii
- Signal Score
- Profiled, not yet scored. Scores are published after regulatory evidence is attached and reviewed. How scoring works
- Headquarters
- Hunt Valley, Maryland, United States
- Website
- https://www.pharm-int.com/
- Modalities
- Sterile Fill-Finish, Lyophilization, Oral Solid Dose, High-Potency APIs, Softgels
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
About Pii
Pii is a contract development and manufacturing organization (CDMO). Capabilities: Sterile Fill-Finish, Lyophilization, Oral Solid Dose, High-Potency APIs, Softgels. 2 manufacturing sites registered with the U.S. FDA, Health Canada and the UK MHRA. Website: https://www.pharm-int.com/
Signal Score
Profiled, not yet scored.
Scores are published after regulatory evidence is attached and reviewed.
How scoring works
Pii FDA Inspection History
2026-03
2024-12
2022-11
2022-11
NAI
VAI
OAI
| Date | Site | Type | Observations | Classification |
|---|---|---|---|---|
| 2026-03-06 |
Pharmaceutics International, Inc.
Cockeysville, Maryland
Company-level
|
Drug Quality Assurance | Yes | Official Action Indicated (OAI) |
| 2024-12-06 |
Pharmaceutics International Inc
Hunt Valley, Maryland
Company-level
|
Drug Quality Assurance | Yes | Voluntary Action Indicated (VAI) |
| 2022-11-14 |
Pharmaceutics International Inc
Hunt Valley, Maryland
Company-level
|
Drug Quality Assurance | No | Voluntary Action Indicated (VAI) |
| 2022-11-14 |
Pharmaceutics International, Inc.
Cockeysville, Maryland
Company-level
|
Drug Quality Assurance | No | Voluntary Action Indicated (VAI) |
Source: FDA Data Dashboard · Retrieved Oct 31, 2026
Pii FDA 483 Findings 13 observations · 2024-12-06 → 2026-03-06 ?
By subsystem
By severity
- 4 — Serious: 2
- 3 — Moderate: 3
- 2 — Minor: 8
- Repeat observations: 0
Most severe findings
-
Cleaning System
"Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the to produce aseptic conditions."
-
Validation lacking for sterile drug products
"Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process."
-
Investigations of discrepancies, failures
"There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed."
Pii MHRA GMP Compliance 2 certificates
2016-02
2016-02
Compliant
Non-Compliant
| Certificate | Site | City / Postcode | Inspection Date | Status |
|---|---|---|---|---|
| UK GMP 22917 Insp GMP 22917/8721389-0002[I] | PHARMACEUTICS INTERNATIONAL INCORPORATED | 21030 | 2016-02-22 | COMPLIANT |
| UK GMP 22917 Insp GMP/IMP 22917/37149-0007[H] | PHARMACEUTICS INTERNATIONAL INCORPORATED | 21031 | 2016-02-22 | COMPLIANT |
Source: MHRA GMDP Database · Retrieved Oct 31, 2026
Hiring Activity Beta
Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data yet. We haven't found a public jobs feed for this company.
Source:
public careers pages
· Checked Oct 30, 2026
Company Signals 10 articles
Company announcements, not verified evidence. They do not change any score.
John Fowler Joins Pharmaceutics International as CEO - citybiz
Jabil Completes Acquisition of Pharmaceutics International, Inc. - PharmTech.com
Pii Expands Prefilled Syringe Services with $3.6M Investment in Capacity and Technology Upgrades - Business Wire
Pharmaceutical Industry Veteran Dr. Kurt R. Nielsen to lead Pharmaceutics International, Inc. (Pii) - PR Newswire
Pharmaceutics International, Inc. (Pii) Receives $93 Million In Growth Capital - PR Newswire
Jabil Acquires Pharmaceutics International, Inc. (Pii) - Business Wire
Manufacturing juggernaut Jabil establishes CDMO presence with M&A play - Fierce Pharma
Jabil Acquires Pharmaceutics International Inc. - Medical Product Outsourcing
Jabil Acquires Pii - Contract Pharma
Pii Announces Serialization Implementation and Readiness - Lelezard
Frequently Asked Questions About Pii
How many FDA inspections does Pii have on record?
CDMO Signal tracks 4 FDA inspections for Pii, sourced from the FDA inspection database. See the full inspection history above.
Has Pii received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Pii.
Does Pii hold EMA or MHRA GMP certificates?
CDMO Signal tracks 2 MHRA GMP certificates for Pii.
Does Pii have a CDMO Signal Score?
Not yet. Pii is profiled, not yet scored. Scores are published after regulatory evidence is attached and reviewed.
Evaluating Pii for a manufacturing program?
Use the free AI matchmaker to compare Pii against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
Similar CDMOs
AbbVie Contract Manufacturing
North Chicago, Illinois, United States
Small Molecule API, High-Potency APIs, Biologics, ADC / Bioconjugation, Sterile Fill-Finish, Lyophilization, Prefilled Syringes, Oral Solid Dose, Hot-Melt Extrusion, Oral Liquids, Topicals
Diamond Animal Health
Des Moines, Iowa, United States
Veterinary, Vaccines, Microbial Fermentation, Viral Antigens, Sterile Fill-Finish, Lyophilization, Non-sterile Liquids, Oral Solid Dose
Quality Chemical Laboratories
Wilmington, North Carolina, United States
Clinical Trial Manufacturing, Oral Solid Dose, Sterile Fill-Finish, Lyophilization
UI Pharmaceuticals
Iowa City, Iowa, United States
Sterile Fill-Finish, Lyophilization, Oral Solid Dose, Clinical Trial Manufacturing
Yichang Humanwell Pharmaceutical
Yichang, Hubei, China
Controlled Substances, Sterile Injectables, Lyophilization, Oral Solid Dose, Softgels, Transdermal Patches, Small Molecule API
Compare Pii with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.